Interaction of Organophosphate Pesticides and Related Compounds with the Androgen Receptor

Hiroto Tamura,1 Hiromichi Yoshikawa,2 Kevin W. Gaido,3 Susan M. Ross,3 Robert K. DeLisle,4 William J. Welsh,5 and Ann M. Richard6

1Department of Applied Biological Chemistry, Meijo University, Nagoya, Japan; 2Department of Environmental Chemistry, Kyushu Kyoritsu University, Kitakyushu, Japan; 3CIT Centers for Health Research, Research Triangle Park, North Carolina, USA; 4Accelrys Inc., Princeton, New Jersey, USA; 5Department of Pharmacology, University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey, USA; 6National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina, USA

Identification of several environmental chemicals capable of binding to the androgen receptor (AR) and interfering with its normal function has heightened concern about adverse effects across a broad spectrum of environmental chemicals. We previously demonstrated AR antagonist activity of the organophosphate (OP) pesticide fenitrothion. In this study, we characterized AR activity of analogues of fenitrothion to probe the structural requirements for AR activity among related chemicals. AR activity was measured using HepG2 human hepatoma cells transfected with human AR plus an androgen-responsive luciferase reporter gene, MMTV-luc. AR antagonist activity decreased as alkyl chain length of the phosphoester increased, whereas electron-donating properties of phenyl substituents of the tested compounds did not influence AR activity. Molecular modeling results suggest that hydrogen-bond energies and the maximum achievable interatomic distance between two terminal H-bond capable sites may influence both the potential to interact with the AR and the nature of the interaction (agonist vs. antagonist) within this series of chemicals. This hypothesis is supported by the results of recent AR homology modeling and crystallographic studies relative to agonist- and antagonist-bound AR complexes. The present results are placed in the context of structure–activity knowledge derived from previous modeling studies as well as studies aimed toward designing nonsteroidal antiandrogen pharmaceuticals. Present results extend understanding of the structural requirements for AR activity to a new class of nonsteroidal, environmental, OP-related chemicals. Key words: androgen receptor, fenitrothion, homology model, HepG2 cells, organophosphates, structure–activity relationships.

Steroid hormone receptors generally refer to ligand-dependent transcriptional regulators controlling the activity of specific gene networks involved in endocrine function (Ing and O’Malley 1995). Evidence is accumulating that some man-made compounds may disrupt normal endocrine function by binding to steroid hormone receptors. Xenoestrogens, for example, not only appear to modulate estrogen-responsive endocrine functions but may also stimulate the growth of estrogen-dependent tumors (Safe and Zacharewski 1992; Wolff and TonioI 1995). In addition, there are reports of environmental contaminants capable of interfering with androgen receptor (AR) function. These include chemicals such as the herbicide linuron (Gray et al. 1997; McIntyre et al. 2000), metabolites of the fungicides vinclozolin (Gray et al. 1998; Kelce et al. 1994; Monosson et al. 1999; Wong et al. 1997) and procymidine (Mekenyan et al. 1997; Osby et al. 1999; Waller et al. 1996a), the insecticide methoxychlor (Gray et al. 1999a) and its metabolite HPTE (Maness et al. 1998), and the DDT metabolite p,p’-DDE (Gray et al. 1999c; Kelce et al. 1995). The structural diversity of these chemicals, many in widespread use, has heightened concern about the potential of other environmental chemicals to disrupt AR function and has led to the development of models and strategies for predicting potential AR activity from chemical structure (Mekenyan et al. 1997; Waller et al. 1996a). Quantitative structure–activity relationship (QSAR) models and qualitative SAR approaches have had some success in identifying and depicting structural features that contribute to the ability of a chemical to interact with steroid hormones, for both the estrogen receptor (ER) (Anstead et al. 1997; Fang et al. 2001; McKinney and Waller 1994; Tong et al. 1997a; Tong et al. 1997b, 1998; Waller et al. 1996b; Wiese and Brooks 1994) and the AR (Loughney and Schwender 1992; Mekenyan et al. 1999; Singh et al. 2000; Tucker et al. 2001; Tucker and Waller 1996). In the case of environmentally occurring chemicals, studies have revealed a common pattern of steric and electronic features involved in molecular recognition and receptor binding affinity, in spite of the molecular diversity of such data sets. Of particular interest to the present study are structural elements important in interactions of nonsteroidal ligands with the AR. Multiple lines of evidence indicate that a substituted phenyl ring, denoted the A-ring in Figure 1, is an essential structural feature in that it acts as an anchor to the molecular recognition site of AR and ER receptors (Anstead et al. 1997; Brzozowski et al. 1997; Marheka et al. 2001; McKinney and Waller 1994; Mekenyan et al. 1997; Pike et al. 2000; Poujol et al. 2000; Waller et al. 1997a). In addition, QSAR models have shown that increased negative charge in the vicinity of the A-ring off the C3 atoms is correlated with increased AR binding affinity (Mekenyan et al. 1997; Waller et al. 1997a). The greatest structural variations in nonsteroidal AR ligands appear in the molecular region that corresponds to the D-ring C17β hydroxyl region (Figure 1) of the natural ligand, dihydrotestosterone (DHT). In this region, QSAR studies find an increase in AR binding affinity correlates with increased negative charge of substituents, and a decrease in AR binding affinity correlates with an increase in steric bulk (Mekenyan et al. 1997; Waller et al. 1997a).

Also pertinent to discerning the structural requirements of AR activity are the results of studies aimed at optimizing antiandrogenic function for the design of pharmaceuticals (Singh et al. 2000; Teutsch et al. 1994; Tucker et al. 1988). The essential rules for antiandrogenic function extracted from these studies are a) an electron-deficient aromatic ring with a strong hydrogen bond (H bond) acceptor (e.g., a nitro or cyano); and b) an aryl-amide linkage to a carbon hosting a strong H-bond donor group at the opposite terminus of the ligand (see, e.g., the essential structural moiety depicted in Figure 2). More
recent publications have reported detailed crystal structures and homology models of AR, ER, and progesterone receptor (PR) ligand-binding domains (LBD) with bound agonist or antagonist ligands. These studies have provided insight into steroid–ligand binding specificity (e.g., AR vs. PR) as well as information on specific residue interactions within the LBD for steroidal and non-steroidal bound ligands (Brzozowski et al. 1997; Marhefka et al. 2001; Matias et al. 2000; Pike et al. 1999; Poujol et al. 2000; Tanenbaum et al. 1998). Taken together, QSAR models and AR binding studies paint a consistent picture of polar substituents at opposite termini of a nonsteroidal ligand framework forming H bonds with appropriate amino acid residues within the binding pocket of the AR.

We investigated the antiandrogenic activity of the organophosphate insecticide fenitrothion [O,O-dimethyl-O-(3-methyl-4-mitrophenyl)phosphorothionate]. Fenitrothion is currently registered by the U.S. Environmental Protection Agency (U. S. EPA) only for non-food uses (e.g., on terrestrial and greenhouse plants and in rat and roach baits), whereas in Japan there is extensive application of fenitrothion to food crops such as rice and fruit [estimated production of 1,230 tons for the year 2000, with estimated half-lives of 22 days and 84 days (at pH 7, 22°C) in soil and water, respectively, and a bioconcentration factor of 246]. Fenitrothion has apparent structural similarities with the pharmaceutical antiandrogen flutamide and the environmental antiandrogens vinclozolin and linuron (Figure 2) but differs most significantly in having a thiophosphonyl group as a proposed H-bond acceptor (Tanenbaum et al. 1998). Taken together, our findings in the context of recently published crystallographic and homology models of the AR-LBD, as well as in relation to prior SAR studies and current hypotheses regarding the structural basis for antiandrogenic activity of nonsteroidal chemicals.

Materials and Methods

Chemicals. Fenitrothion, methyl parathion, and 3-methyl-4-nitrophenol were obtained from Chem Service (West Chester, PA, USA). Other organophosphorus derivatives were synthesized according to published methods (Nishizawa et al. 1961). The structure of the synthesized compounds was determined as follows: 1H NMR spectra were obtained on a JEOL EX400 spectrometer (JEOL, Tokyo, Japan) using tetramethylsilane as an internal standard. Infrared and UV spectra were recorded on a Perkin-Elmer Spectrum RX III FT-IR (Perkin-Elmer, Beaconsfield, Bucks, UK) and Shimadzu UV-240 spectrophotometer (Shimadzu, Kyoto, Japan), respectively. Spectral data were consistent with assigned structures. Refractive index was measured using a 1T Abbe Refractometer (ATAGO Co., Tokyo, Japan). All other chemicals were obtained from Sigma Chemical Company (St. Louis, MO, USA). All chemicals were > 97% pure.

Plating and transfection. We performed transfection experiments as previously described (Maness et al. 1998; Tamura et al. 2001). Briefly, human hepatoma HepG2 cells (ATCC, Rockville, MD, USA) were plated in triplicate in 24-well plates (Falcon Plastics, Oxnard, CA, USA) at a density of 10^5 cells/well in complete medium (phenol red-free Eagle’s minimal essential medium; Gibco/BRL, Grand Island, NY, USA) supplemented with 10% resin-stripped fetal bovine serum (HyClone, Logan, UT, USA), 2% l-glutamine, and 0.1% sodium pyruvate and allowed to incubate overnight at 37°C in a humidified atmosphere of 5% CO_2/air. Cells were then transfected as previously described (Maness et al. 1998) (SuperFect; Qiagen, Valencia, CA, USA, or TransIT; Mirus Co., Madison, WI, USA) with three plasmids: a) 10 ng/well human AR, b) 405 ng/well MMTV-luc reporter plasmid, and c) 40 ng/well pCMVβ-gal plasmid as a transfection and toxicity control. Cells were placed in a 37°C incubator with a humidified atmosphere of 5% CO_2/air for 3 hr. The transfected cells were then rinsed with phosphate-buffered saline and treated with various concentrations of test chemical from 10^{-8} to 10^{-5} M for determination of AR agonist activity.

We performed dose-shift experiments for the determination of AR antagonist potency by adding set concentrations of test chemical (10^{-7}, 10^{-6}, 10^{-5} M) across a complete dose–response range of the natural ligand dihydrotestosterone (DHT). A vehicle control was included in each experiment (dimethyl sulfoxide; Sigma) in complete medium. Final concentration of dimethyl sulfoxide in medium was 0.1%. After a 24-hr incubation, treated cells were rinsed with phosphate-buffered saline and lysed with 65 μL of lysis buffer (25 mM tris-phosphate, pH 7.8, 2 mM 1,2-diamino-cyclohexane-N,N,N’,N’-tetraacetic acid,
10% glycerol, 0.5% Triton X-100, 2 mM dithiothreitol). Lysate was divided into two 96-well plates for luciferase and β-galactosidase activity determination.

**Enzyme activity assay.** We added luciferase assay reagent (100 µL; Promega, Madison, WI, USA) to 20 µL of lysate and determined luminescence immediately using an ML3000 microtiter plate luminometer (Dynatech Laboratories, Chantilly, VA, USA). For β-galactosidase activity determination, 20 µL of a 4 mg/mL solution of chlorophenol red-β-D-galactopyranoside (CPRG; Sigma) and 150 µL CPRG buffer (60 mM Na₂HPO₄, 40 mM NaH₂PO₄, 10 mM KCl, 1 mM MgSO₄, 50 mM β-mercaptoethanol, pH 7.8) was added to 30 µL of lysate. Absorbance at 570 nm was determined over a 30-min period using a V_{max} kinetic microplate reader (Molecular Devices, Menlo Park, CA, USA).

**Statistical analysis.** Unless otherwise noted, measured activities presented in this study represent the means ± SE resulting from at least three separate experiments with triplicate wells for each treatment dose. We analyzed dose–response data using the sigmoidal dose–response function of the graphical and statistical program Prism (GraphPad, San Diego, CA, USA). The equilibrium dissociation constant (K_{d}) for the antagonist–receptor complex was determined by Schild regression analysis of the dose ratio as previously described (Maness et al. 1998; McIntyre et al. 2000; Tamura et al. 2001). The dose ratio is [A]/[A], where [A] and [A] refer to equiactive concentrations of DHT in the presence and absence of antagonist, respectively (Kenakin 1993).

**Computation of structural properties.** We calculated ligand interatomic distances and H-bond energies using the SPARTAN molecular modeling software (version 5.1.1 for UNIX; Wavefunction, Inc., Irvine, CA, USA). Geometries of studied molecules were fully optimized using the semiempirical PM3 method (Stewart 1998). To sample the range of thermodynamically achievable distances between putative H-bond acceptor sites, limited conformational space was explored by constraining the two putative H-bond acceptor atoms to a fixed distance apart, allowing the remainder of the molecule to relax to the lowest energy configuration, followed by release of the original constraint allowing full relaxation in the extended conformation. We tabulated distances between putative H-bond acceptor sites, atomic charges at these sites, and total molecular energies of the conformers. We estimated H-bond interaction energies of the putative donor and acceptor sites on the natural AR ligand, DHT, and selected nonsteroidal analogues using the PM3 method to compute the energies of interaction with a single water molecule at each site; PM3 fully optimized conformations of the water-bound species were computed for this purpose.

**Results**

**Androgen receptor antagonist activity.** We examined the interaction of a select group of fenitrothion derivatives with the AR (Table 1). Mean maximal luciferase activity achieved at 10⁻⁷ M DHT across all experiments was 4,889 ± 967 with an interassay coefficient of variation (CV) of 48%. This represents a 163-fold induction over background. When experiments were normalized to percent response, with 100% being the maximal level of induction within each individual experiment, the interassay CV in the linear portion of the curve (5 × 10⁻⁷ M DHT) was 13%. At this same dose (5 × 10⁻⁷ M DHT), the within- assay (replicate wells) CV averaged 17% across all experiments.

Of the compounds tested in this study, only methylparathion 3 and ethylfenitrothion 5 demonstrated sufficient AR antagonistic activity to determine potency in dose-shift experiments (Figure 3). Methylparathion and ethylfenitrothion both caused parallel shifts in DHT dose–response curves indicating that, similar to fenitrothion, they are competitive AR antagonists. Equilibrium dissociation constants (K_{d}) (Kenakin 1993) for methylparathion and

---

**Table 1. Equilibrium dissociation constants (K_{d}) of organophosphate compounds and structurally related androgen receptor antagonists.**

| Chemical name | No. | R₁ | R₂ | R₃ | X | K_{d} (10⁻⁸ M) |
|---------------|-----|----|----|----|---|----------------|
| Fenitrothion   | 1   | CH₃| NO₂| CH₃| S | 2.18           |
| Methylparathion| 2   | CH₃| NO₂| CH₃| O | ND             |
| Methylparathion| 3   | CH₃| NO₂| H  | O | 35.9           |
| Methylparathion| 4   | CH₃| NO₂| H  | O | ND             |
| Methylparathion| 5   | CH₃| NO₂| CH₃| S | 16.5           |
| Ethylparathion | 6   | CH₃| NO₂| H  | O | ND             |
| Ethylparathion | 7   | CH₃| NO₂| H  | O | ND             |
| Ethylparathion | 8   | CH₃| NO₂| H  | O | ND             |
| Ethylparathion | 9   | CH₃| NO₂| [CH₂–O] | S | ND |
| Ethylparathion | 10  | n-C₃H₇| NO₂| CH₃| S | ND |

* Data from Tamura et al. (2001). ND = K_{d} was not detected at the concentration of 1 × 10⁻¹⁵ M. Refer to Figure 2 for chemical structures. # Data from Maness et al. (1998). $ Data from McIntyre et al. (2000).

---

**Figure 3.** Methylparathion and ethylfenitrothion act as competitive reversible inhibitors of AR. HepG2 cells were transfected with human AR plus an AR-responsive luciferase reporter gene and a constitutively active β-galactosidase reporter gene (transfection and toxicity control). Transfected cells were treated with 10⁻¹⁰ to 10⁻⁵ M DHT either alone or in combination with 3 × 10⁻⁷ M, 10⁻⁶ M, and 3 × 10⁻⁶ M methylparathion (A) or ethylfenitrothion (B). Values represent the means ± SE of three separate experiments and are presented as percent response, with 100% activity defined as the activity achieved with 10⁻⁷ M DHT alone in each experiment.
ethylfenitrothion were determined as previously described (Maness et al. 1998; McIntyre et al. 2000; Tamura et al. 2001) and are presented in Table 1. Cytotoxicity was not observed for any of the tested compounds in the selected dose range (data not shown).

Methylparathion 3, which differs from fenitrothion 1 only by absence of the m-methyl substitution on the phenyl ring, was approximately 16-fold less potent than fenitrothion (Table 1). Similarly, ethylfenitrothion 5 demonstrated AR antagonist activity, whereas ethylparathion 6 gave no detectable antiandrogenic activity up to a maximum concentration of 10⁻⁵ M (Table 1). These results indicate that m-methyl substitution enhances AR antagonist activity of this class of compounds.

Ethylfenitrothion 5 was 8-fold less potent than fenitrothion 1 (Table 1). The n-propyl ester derivative 10 displayed weak AR antagonist activity; however, toxicity of this compound > 10⁻⁵ M interfered with our ability to perform experiments necessary to determine 

### Table 2. Calculated properties of dihydrotestosterone (DHT) in relation to fenitrothion and known androgen antagonists.

| Chemical structure | Relative energy (kcal/mol) | Distance (Å) | Atomic charge | H bond (kcal/mol) |
|--------------------|---------------------------|--------------|---------------|------------------|
| DHT                |                           |              |               |                  |
| [Diagram]          | 0.00                      | 10.48        | -0.31         | -3.70            |
|                    | 0.36                      | 10.00        | -0.30         | -3.14            |
| Fenitrothion       |                           |              |               |                  |
| [Diagram]          | 0.00                      | 8.18         | -0.60         | -3.33            |
|                    | 1.68                      | 9.50         | -0.58         | -0.17            |
|                    |                           |              |               | -2.17            |
| Flutamide          |                           |              |               |                  |
| [Diagram]          | 0.00                      | 7.50         | -0.58         | -2.91            |
|                    | 2.48                      | 8.00         | -0.33         | -2.97            |
| Hydroxyflutamide   |                           |              |               |                  |
| [Diagram]          | 0.00                      | 8.94         | -0.58         | -2.96            |
|                    | 1.72                      | 9.50         | -0.35         | -3.20            |
|                    |                           |              |               | -2.95            |
| Linuron            |                           |              |               |                  |
| [Diagram]          | 0.00                      | 9.16         | -0.34         | -3.25            |
|                    | 1.65                      | 9.50         | -0.22         | -2.85            |

*Relative energies of PM3 (Stewart, 1998) optimized geometries; E = 0.00 kcal/mol corresponds to fully optimized equilibrium configuration; whereas second energy corresponds to energy when x–z distance is constrained (e.g., 10 Å for DHT) and rest of molecule is allowed to relax. Distance between most separated H-bonding centers (O or S) in equilibrium or constrained configuration. Mulliken atomic charges at equilibrium geometry. H-bond interaction energies, E(Product-E(ligand)), computed using PM3 method, using fully optimized structures of water, ligand, and merged water–ligand product. Distance of x–y H-bonding centers corresponding to the constrained configuration with x–z distance of 9.5 Å.
other four molecules) of the distance between H-bond centers with relatively little energy cost. However, all four of the nonsteroidal compounds fall short of the ≧ 10 Å separation of H-bond centers calculated for DHT. Of the four, flutamide has the shortest computed distance (8 Å) between H-bond oxygen centers, falling a full 2 Å short of the DHT template for the AR ligand binding interaction. Each of the remaining three nonsteroidal compounds can achieve a relatively stretched configuration (9.5 Å between the most distant H-bond centers) with small energy cost (< 1.8 kcal/mol), to within 0.5 Å of the lower bound for DHT. Of these three compounds, only linuron has no measurable agonist activity (McIntyre et al. 2000).

An important structural and functional distinction between fenitrothion and DHT is the thiol as a putative H-acceptor center in fenitrothion versus the C17β hydroxyl in DHT. Estimated energies and distances associated with H bonds formed between a water molecule and possible H-bond sites are listed in the last three columns of Table 2. Comparison of the calculated H-bond energies and distances corresponding to the most distant center for fenitrothion and hydroxysteramide indicates a smaller H-bond energy for the sulfur (−2.17 vs. −2.95 kcal/mol), but also a 1 Å longer H-bond distance (2.83 vs. 1.83 Å). Hence, the smaller H-bond interaction energy may be offset by a more easily achieved H-bond distance for fenitrothion versus hydroxysteramide. If the extra 1 Å H-bond distance is factored into the overall distance between H-bond centers, fenitrothion extends to the 10 Å range of the DHT template.

**Discussion**

The present study focused on identifying and characterizing the structural basis for the interaction of organophosphorus-related chemicals with the AR. In attempting to further elucidate the AR binding mechanism of organophosphorus-like ligands, such as fenitrothion, it is important to consider a proposed binding mechanism in the context of what is known generally about steroid hormone receptor function, as well as specifically about polar residue interactions of bound ligands in the AR-LBD.

A “mouse trap” mechanism based on crystallographic studies of ligand-binding interactions has been proposed as a model for ligand-receptor binding within the nuclear steroid hormone superfamily (Brzozowski et al. 1997; Buchanan et al. 2001; Goldstein et al. 1993; Renaud et al. 1995; Wurtz et al. 1996). Briefly, the ligand is trapped from the bulk solution at the entrance of the ligand-binding pocket and brought into and locked at the binding site by interaction with amino acid residues within the receptor through H-bond and hydrophobic interactions. This leads to formation of an AR homodimer with two bound ligands, which induces additional conformational transitions leading to a more compact receptor structure and a transcriptionally active ligand-receptor homodimer complex. The specifics of the ligand binding interaction vary with each of the nuclear steroid hormone receptors, but in all cases the carboxy-terminal helix 12 appears to play a crucial role in determining agonist or antagonist activity. In the case of a bound agonist, helix 12 acts as a “lid” that swings around to entrap the ligand in the LBD, effecting the necessary conformational change for transcription to occur (Brozowski et al. 1997; Buchanan et al. 2001; Matias et al. 2000). In the case of a bound antagonist, the helix 12 lid is prevented from closing and the entrance to the LBD remains open, thus preventing transcriptional activation (Brozowski et al. 1997; Buchanan et al. 2001; Marhefka et al. 2001; Pike et al. 1999). With retinoic acid (Figure 2) and retinoid X receptors (RXR), it is believed that the carboxylate group of retinoic acid enters the ligand-binding pocket first and is drawn down the hydrophobic cleft to its anchoring site. Both the H bond at the carboxylate group site and Van der Waals interaction at the β-ionone ring site stabilize the ligand (Renaud et al. 1995; Wurtz et al. 1996). Likewise, for 17β-estradiol (Figure 2), the 3-OH group of the A-ring and the C17β hydroxyl oxygen of the D-ring both act as anchoring elements and H-bond donors within ER (Brzozowski et al. 1997; Pike et al. 1999; Tanenbaum et al. 1998). For the DHT-AR interaction, the carbonyl oxygen of the A-ring acts as an H-bond acceptor, whereas the C17β hydroxyl oxygen of the D-ring could act as either an H-bond donor or acceptor (Figure 2) (Marhefka et al. 2001; Matias et al. 2000).

Specifically in reference to the AR-LBD, it had been inferred from DNA sequence homology (Wurtz et al. 1996) and mutation studies (Doeburg et al. 1997; Gottlieb et al. 1998; Taplin et al. 1999; Wurtz et al. 1996) that the carbonyl oxygen of the A-ring and the C17β hydroxyl oxygen of the D-ring in DHT most likely interact through H-bonds with Arg752 in helix 5 and Thr877 in helix 11 in AR-LBD, respectively, because mutation of these residues caused a complete androgen-insensitivity syndrome (Sultan et al. 1993) and altered ligand specificity (Veldscholte et al. 1990). Recent crystallographic determination of the AR-LBD bound to a steroidal-type ligand (R1881), and a more recent homology modeling study that considered a variety of nonsteroidal AR ligands bound to the LBD, provide evidence to support and refine this view (Marhefka et al. 2001; Matias et al. 2000). Both studies reported H-bonding interactions of the A-ring polar group of bound AR ligands with Arg752, mediated by one or two bound water molecules. On the opposite terminus of the molecule, the crystallographic study provided evidence of H bonding between the C17β hydroxyl group of R1881 with two polar residues: the carbonyl oxygen of Asn705 and the hydroxyl oxygen of Thr877 (Matias et al. 2000). The subsequent AR homology study (Marhefka et al. 2001) considered a broader variety of bound nonsteroidal ligands and found different possible binding modes within this C17β-OH region, indicating the possibility of either an H-bond donor or acceptor interaction of the ligand with Thr877. Hence, we propose that the mechanism for the fenitrothion thiol to act as an H-bond acceptor in the D-ring 17β-OH region of the AR-LBD likely involves interaction with the Thr877 residue of helix 11. We speculate further that the amide nitrogen of Arg752 could possibly act as an H-bond donor in interaction with the fenitrothion thiol. Comparison of a putative three-dimensional binding orientation of fenitrothion compared to DHT in the AR-LBD is represented schematically in Figure 4.

Regarding the mechanism of activation of the AR by agonist ligands, Thr877 is located within helix 11 in close apposition to helix 12. We speculate that by establishing favorable interactions with Thr877 (as well as other residues within this domain, specifically Asn705), the ligand effectively stabilizes this region of the AR. The result is to enhance the overall probability of helix 12 favorably orienting into an activated position. Analysis of two independently elucidated crystal structures of the AR [Protein DataBank (PDB) accession numbers 1I38 (Sack et al. 2001) and 1E3G (Matias et al. 2000)] reveals a distance of approximately 15.2 Å between the H-bonded terminal nitrogen of Arg752 and the hydroxyl oxygen of Thr877, thus providing requisite dimensions within the AR-LBD (Figure 5). Allowing a maximum of 2.5–3.0 Å from each of these atoms to form stable H bonds suggests a separation distance of 9.2–10.2 Å between H-bonding groups present on candidate ligands, with the lesser of these values approaching the limit of stability for H bonding. It can be inferred that ligands that are unable to achieve thermodynamically stable conformations within these dimensional constraints will have reduced capacity to transcriptionally activate the AR and produce agonist effects.

The present analysis considers the conformationally stretched distance between polar H-bond capable sites of known AR antagonists to be a measure of the potential of a molecule to express additional agonist properties. We henceforth refer to this as the “near 10 Å polar interactions rule.” Why is it
important to consider potential agonist properties if these appear secondary to antagonist activity and are detected only at high doses in the absence of effective competition with natural ligand (Maness et al. 1998; Tamura et al. 2001)? How can we interpret this information mechanistically and in the context of a risk evaluation? Referring to the schematic representation of the AR-LBD in Figure 4, we consider the three main binding elements likely required for antagonist and/or agonist activity. In common with other known AR antagonists, fenitrothion and its organophosphorus-like AR antagonist analogues all contain the essential A-ring phenyl feature with a putative strong H-bond interaction site. We posit that structures that can achieve, in addition, effective hydrophobic and steric interactions in the central binding region of the LBD are necessary for AR antagonism.

Recent elucidation of the AR-LBD with bound ligands confirms a central binding region of nonpolar residues that is predicted to tolerate more bulky, hydrophobic substituents (Marhefka et al. 2001; Matias et al. 2000). However, structural constraints are clearly important for conferring sufficient and optimum binding affinity to produce antagonism. This contention is supported by the results of an earlier study aimed at designing high-affinity nonsteroidal antiandrogens with purely antiandrogenic activity for clinical application (i.e., with no agonist effects or cross hormonal interactions) (Teutsch et al. 1994). Selected members of the class of N-substituted arylthiohydroxydantoins, analogues of the common antiandrogen therapeutic agent nilutamide, were found to have exceptionally high relative binding affinities to the AR, similar to DHT. The structural modifications from previously known antagonists were primarily in the D-ring region, involving a thioamide replacement of an amide. These compounds did not, however, provide a good candidate feature for D-ring H-bond interaction according to the “near-10 Å polar interaction rules” (the thiol was computed to be a 7.5 Å separation from the A-ring H-bond acceptor site), which is consistent with lack of reported agonist properties.

The importance of essential structural elements in the central binding region is also supported by the observed 15-fold increase in binding affinity for fenitrothion versus methylparathion upon A-ring substitution of a hydrogen for a methyl at the R3 A-ring position (see Table 1). Previous authors suggested that electron-withdrawal properties of the R3 phenyl substituent enhancing the H-bond acceptor capability at the R2 position are important for antagonism (Singh et al. 2000; Teutsch et al. 1994; Tucker et al. 1988). In contrast, the authors of a recent AR homology study counter that the steric/hydrophobic interaction aspects of this substituent are more important components for binding (Marhefka et al. 2001), a view more consistent with the present findings.

For the last of the three AR-LBD binding elements, multiple lines of evidence implicate a strong H-bond interaction in the vicinity of the D-ring (C17-) LBD binding region as being a necessary, but not sufficient, requirement for AR agonist activity. SAR evidence gathered from previous study of an extensive series of nonsteroidal antiandrogens (Tucker et al. 1988), some with both agonist and antagonist properties, is consistent with this view. In that study, more than 70 compounds were synthesized and tested. all 3-(substituted thio)-2-hydroxypropionanilides (HPAs) containing the essential structural moiety illustrated in Figure 2 with an additional polar hydroxyl substituent on X. A key finding of that study in relation to the present work is that the electron-withdrawing capability of the substituent opposite to the hydroxyl group on X determined whether the molecule had agonist effects in addition to antagonist effects: Compounds with CF3 substituents were agonists/antagonists, whereas the same compounds with CH3 substituents had no agonist properties and a 2- to 3-fold reduction in antagonism. The clear implication is that the X-OH becomes a stronger H-bond donor with the additional CF3 substituent and therefore, is more likely to enhance the D-ring region interaction necessary to produce agonism. In comparison to our own work, the HPAs can be viewed as structurally analogous to hydroxyflutamide, with the same essential structural moiety yielding the same distance separations between H-bond capable polar groups as in hydroxyflutamide (Figure 2 and Table 2). Hence, all of the HPAs examined satisfy our proposed distance requirement for potential C17β-OH region interaction, and all are reportedly antagonists, but only those chemicals with sufficiently strong H-bond interaction potential in the D-ring region have additional agonist activity.

A recent study that considered the binding of steroidal and nonsteroidal ligands to a double mutant form of the AR sheds further light on the multiple factors controlling the potential for a ligand to exhibit AR agonism (Matias et al. 2002). Mutations of Thr877 (Ala) and Leu701 (His) in the D-ring region were shown to inhibit binding of the natural ligand, DHT, and to significantly enhance binding and agonist properties of steroidal cortisols, as well as hydroxyflutamide. Crystallographic evidence, as well as energy minimization calculations, indicates that the altered residues in the double mutant AR significantly reduce unfavorable steric interactions of these bound ligands in the D-ring region (i.e., interactions that normally prevent or inhibit helix 12 closure and agonism in the wild-type AR) (Matias et al. 2002). Particularly with regard to agonistic activity...
of hydroxylfluamide under different experimental conditions, these results indicate further modulation and sensitivity of agonism to subtle steric and conformational influences in the D-ring binding region.

The implication of these arguments is that fenitrothion, because it is capable of acting either as an AR antagonist or agonist, depending on the experimental conditions (competitive or noncompetitive binding), is capable of satisfying all three binding requirements for AR-LBD interaction, but only under selected conditions. With no reported evidence to suggest allosteric binding mechanisms for AR activity, and evidence pointing to the ability of nonsteroidal AR ligands to effectively bind in the AR-LBD (Marhefka et al. 2001), we posit that AR agonism is only observed at high doses of ligand due to the probabilistic nature of the AR binding interaction. The probability of initially encountering the AR has a first-order dependence on dose of ligand ($P_d$). Second is the probability of being drawn into the AR-LBD cavity and binding in some fashion ($P_b$); fenitrothion likely has a lower $P_b$ than the natural DHT ligand due to sub-optimal binding affinity in the A-ring and central hydrophobic regions. Finally, the conformational flexibility of fenitrothion and other nonsteroidal AR ligands introduces a third probabilistic component. In the partially AR-bound state, fenitrothion has a less than unit probability ($P_s$) of achieving the stretched configuration for optimal H-bonding interaction in the C17β hydroxyl region that is presumed necessary for AR transcriptional activity; achieving this configuration will depend on the local molecular dynamics forces within the AR-LBD. Hence, with sub-optimal binding (i.e., satisfying only two of the three binding elements), antagonism is the predicted and more probable outcome (the product of the fractional probabilities $P_d \times P_b \times P_s$). Because agonism requires the third binding element also to be achieved (i.e., the “near 10 Å polar interactions rule”), it is a less probable event (i.e., $P_d \times P_b \times P_s$). Because overall probabilities for observing either antagonism or agonism increase with increasing dose of fenitrothion (i.e., $P_s$), the overall probability of observing agonism, if achievable, will be greatest at the highest fenitrothion doses. The implications for hazard assessment are that nonsteroidal chemicals should be screened for all three of the binding elements for AR-LBD interaction, and those compounds predicted to satisfy all three elements and effect transcription (i.e., act as agonists) may be of greater concern.

A final point concerns the comparison of different quantitative and qualitative measures of androgenic activity across a variety of assays and test systems for the purposes of generating SAR hypotheses and prediction models. If quantitative activities (e.g., relative binding affinities) are used in deriving a potency prediction model, clearly these must be for a validated and uniform measure of androgenic activity. Unfortunately, the available data are not uniform in this sense and represent a variety of measures across a variety of test systems (e.g., Singh et al. 2000). This accounts for the relatively limited data sets used in previously reported QSAR models for predicting androgenic activity of environmental chemicals. For the purposes of qualitative identification of important SAR features and structural elements relative to AR activity, however, we believe that comparisons can be made across diverse data sets provided that one uses only relative information extracted from within those data sets (e.g., in considering the structural features that distinguish agonist from antagonist activity among the HPAs) (Tucker et al. 1988). Prior SAR investigations aimed at understanding and optimizing the activity of nonsteroidal antiandrogens contain a wealth of potentially useful information (Singh et al. 2000; Teutsch et al. 1994; Tucker et al. 1988). These data can and should be considered in efforts to generate useful hypotheses and appropriate model constraints for screening of environmental compounds for potential androgenic activity.

The results of this study have important implications for future attempts to construct SAR models for predicting potential androgenic activity. First, conformational flexibility of potential ligands should be considered in light of the determining constraints for optimal AR interaction—namely, the ability to achieve a suitable distance separation of polar interaction groups (approximately 10 Å) at low energy cost. If conformational flexibility is not taken into account, AR homology models and other types of SAR screens may fail to detect the potential for AR binding interaction. Second, the demonstrated AR antagonist activities of fenitrothion, methylparathion (3), and ethylfenitrothion (5) provide compelling evidence that the thiophosphonyl group bears sufficient analogy to the hydroxylamide moiety of hydroxylfluamide as to similarly satisfy AR-LBD binding elements for both antagonism and agonism. This is despite the different H-bonding interactions predicted for the thiol H-bond acceptor in fenitrothion versus the hydroxyl H-bond donor in hydroxyfluamide or DHT within the AR-LBD. Third, the results reported in Table 1 for a series of organophosphorus-like chemicals point to structural features that either determine or enhance the ability of these compounds to act as AR antagonists. These results expand our knowledge of structural binding elements that can be accommodated by the AR-LBD and that should be considered in future efforts to develop general screens for AR activity of environmental chemicals.

**References**

Anstead GM, Carlson KE, Katzenellenbogen JA. 1997. The androgen pharmacophore: Structural and estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62:288–303.

Buchanan G, Yang M, Harris HM, Nahm HS, Han G, Moore N, et al. 2001. Mutations at the binding interface of the androgen and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15:46–56.

Bzowiczowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Enstrom D, et al. 1997. Mutations of gene 11 and antagonism in the oestrogen receptor. Nature 389:753–758.

Doeubert P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, et al. 1997. Functional in vivo interaction between the amino-terminal transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36:1052–1064.

Eto M, ed. 1974. Organophosphorous Pesticides: Organic and Biological Chemistry. New York:CRC Press.

Fang H, Tong W, Shi LM, Blair R, Perkins R, Branham W, et al. 2001. Structure–activity relationships for a large diverse set of natural, synthetic, and environmental estrogens. Chem Res Toxicol 14:280–294.

Goldstein RA, Katzenellenbogen JA, Luthy-Schulten ZA, Seisleid DA, Wolyne PS. 1993. Three-dimensional model for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 90:7957–7961.

Gottlieb T, Lehlvasalho H, Beitek L, Lumbroso R, Pinsky L, Trifirò M. 1998. The androgen receptor gene mutations database. Nucleic Acids Res 26:224–238.

Gray LE Jr, Ostby J, Cooper RL, Kelce WR. 1999a. The estrogenic and antiandrogenic pesticide methoxychlor alters the reproductive tract and behavior without affecting pituitary size or LH and prolactin secretion in male rats. Toxicol Ind Health 15:37–43.

Gray LE Jr, Ostby J, Monosson E, Kelce WR. 1999b. Environmental antiandrogens: low doses of the fungicide vinclozolin alter sexual differentiation of the male rat. Toxicol Ind Health 15:48–60.

Gray LE Jr, Wolf C, Lambright C, Mann P, Price M, Cooper RL, et al. 1998c. Administration of potentially antiandrogenic pesticides (procymidone, imuron, proldione, chlorizolate, p,p′-DDE, and ketozanazole) and toxic substances (dibutylyl and diethyhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol Ind Health 15:94–118.

Ing NH, O’Malley BW. 1995. The steroid hormone receptor superfamily–molecular mechanism of action. In: Molecular Endocrinology: Basic Concepts and Clinical Correlations (Weintraub B, ed). New York:Raven Press, 196–215.

Kelce WR, Monosson E, Gamsckip MP, Laws SC, Gray LE Jr. 1994. Environmental hormone disruptors: evidence that vinclozolin developmental toxicity is mediated by antiandrogenic metabolites. Toxicol Appl Pharmacol 126:276–285.

Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. 1995. Persistent DDT metabolite p,p′-DDE is a potent androgen receptor antagonist. Nature 375:581–585.

Kenakin T. 1993. Competitive antagonism. In: Pharmacologic Analysis of Drug-Receptor Interaction (Kenakin T, ed). New York:Raven Press, 279–322.

Loughney DA, Schwindner CF, et al. A comparison of progesterin and androgen receptor binding using the CoMFA technique. J Comput Aided Mol Des 6:569–581.

Maness SC, McDonnell DP, Gaido KW. 1998. Inhibition of androgen receptor–dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. Toxicol Appl Pharmacol 151:135–142.

Marhefka CA, Moore BM, Bishop TC, Kirkovsky L, Mukherjee A, Dalton J, et al. 2001. Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosteronone and nonsteroidal ligands. J Med Chem 44:1729–1740.

Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, et al. 2002. Structural basis for the glucocorticoid response in a mutant human androgen receptor (ARCVV) derived from an androgen-independent prostate cancer. J Med Chem 45:1430–1446.

Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, et al. 2000. Structural evidence for ligand specificity in the binding domain of the human androgen receptor.
Implications for pathogenic gene mutations. J Biol Chem 275:26164–26171.

McIntyre BS, Earlow NJ, Wallace DG, Maness SC, Gaido KW, Foster PDM. 2000. Effects of in utero exposure to linuron on androgen-dependent reproductive development in the male CrlCD(SD)BR rat. Toxicol Appl Pharmacol 167:87–99.

McKinney JD, Waller CL. 1994. Polychlorinated biphenyls as hormonally active structural analogues. Environ Health Perspect 102:290–297.

Mekenyan OG, Ivanov JM, Karabunarliev SH, Bradbury SP, McKinney JD, Waller CL. 1994. Polychlorinated biphenyls as antagonists (antiandrogens): structure activity relationships. Curr Med Chem 7:211–247.

Singh MS, Gauthier S, Labrie F. 2000. Androgen receptor antagonists (antiandrogens): structure–activity relationships. J Steroid Biochem Mol Biol 74:493–514.

Tong W, Lowis DR, Perkins R, Chen Y, Welsh WJ, Goddette DW, et al. 1998. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 38:669–677.

Waller CL, Juma BW, Gray LE Jr, Kelce WR. 1996a. Three-dimensional quantitative structure-activity relationships for antiandrogen receptor ligands. Toxicol Appl Pharmacol 137:219–227.

Waller CL, Oprea TI, Chae K, Park HK, Korach KS, Laws SC, et al. 1996b. Ligand-based identification of environmental estrogens. Chem Res Toxicol 9:1240–1248.

Wiese TE, Brooks SC. 1994. Molecular modeling of steroid estrogens: novel conformations and their role in biological activity. J Steroid Biochem Mol Biol 50:61–73.

Wolff MS, Toniolo PD. 1995. Environmental organochlorine exposure as a potential etiologic factor in breast cancer. Environ Health Perspect 103(suppl 7):141–145.

Wong C, Kelce WR, Sar M, Wilson EM. 1995. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 270:19998–20003.

Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, et al. 1996. A canonical structure for the ligand-binding domain of nuclear receptors. Acta Crystallogr Sect D: Biol Crystallogr 52:194–202.

Safe SH, Zacharewski T. 1997. Organochlorine exposure and risk for breast cancer. Prog Clin Biol Res 396:133–145.

Singh MS, Gauthier S, Labrie F. 2000. Androgen receptor antagonists (antiandrogens): structure–activity relationships. Curr Med Chem 7:211–247.

Stewart JUP. 1998. Optimization of parameters for semiempirical methods. J Comp Chem 19:209–220.

Sultan C, Lumbroso S, Poujol N, Belon C, Boudon C, Lobaccaro JM. 1993. Mutations of androgen receptor gene in androgen insensitivity syndromes. J Steroid Biochem Mol Biol 46:519–530.

Tamura H, Maness SC, Reischmann KP, Dorman D, Gray LE Jr, Gaido KW. 2001. Fenretinide: androgen receptor antagonism by the organophosphate insecticide fenitrothion. Toxicol Sci 56:62–66.

Tanenbaum DM, Wang Y, Williams SP, Sigler PB. 1998. Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains. Proc Natl Acad Sci USA 95:5998–6003.

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, et al. 1999. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511–2515.

Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cereda E. 1994. Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 48:111–119.

Tong W, Perkins R, Strelitz R, Collantes ER, Keenan S, Welsh WJ, et al. 1997a. Quantitative structure–activity relationships (QSARs) for estrogen binding to the estrogen receptor: predictions across species. Environ Health Perspect 105:1116–1124.

Tong W, Perkins R, Xing L, Welsh WJ, Sheehan DM. 1997b. QSAR models for binding of estrogenic compounds to estrogen receptor alpha and beta subtypes. Endocrinology 138:4022–4025.

Tong W, Lowis DR, Perkins R, Chen Y, Welsh WJ, Goddette DW, et al. 1998. Evaluation of quantitative structure-activity relationship methods for large-scale prediction of chemicals binding to the estrogen receptor. J Chem Inf Comput Sci 38:669–677.

Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. 1990. A mutation in the ligand-binding domain of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904–4909.

Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. 1990. A mutation in the ligand-binding domain of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904–4909.

Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. 1990. A mutation in the ligand-binding domain of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904–4909.

Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, et al. 1990. A mutation in the ligand-binding domain of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904–4909.